Comparison between High-Dose Pitavastatin and Moderate-Dose Pitavastatin combined with Ezetimibe on LDL-C Levels in Type II Diabetics.

Objective: To compare pitavastatin 4 mg (high dose) with 2 (moderate and ezetimibe combination on LDL-C in type II diabetics. Study Design: Setting: National Medical Center (NMC) PNS Shifa Hospital. Period: January June 2022. Material & Methods: Fifty diagnosed diabetics metformin, 25 the monotherapy group (group A) therapy B). Glycosylated hemoglobin lipid profile tests were conducted labs pre 3 months post therapy. levels recorded compared. Result: Average level drop of 13.51% occurred 17.48% group. Chi square test showed that target (< 130 mg/dl) reached 33% patients 64% Conclusion: Pitavastatin both lowered levels, however, by a greater degree larger number people.